When Martin Makary, President Trump's nominee to lead the Food and Drug Administration, appeared before the Senate for his confirmation hearing, he declined to state plainly whether the president could ever be wrong, according to reporting by Ars Technica. The exchange, brief as it apparently was, landed with unusual weight given the institution Makary has been nominated to run.
The FDA occupies a peculiar place in American governance. It is a regulatory body whose authority rests almost entirely on public trust in its independence from political pressure. Drugs, vaccines, food safety determinations, medical device approvals — each of these touches the daily lives of hundreds of millions of people, and the credibility of those decisions depends on the perception, and the reality, that science rather than political loyalty is driving them. That credibility has been built over decades, and it has also been damaged before. The agency's handling of opioid approvals, its pandemic-era stumbles, and periodic accusations of regulatory capture by industry have all taken bites out of the institutional trust the FDA depends upon.
What makes Makary's deflection notable is the specific moment it occupies. The Trump administration has been unusually explicit in its desire to reshape federal scientific and regulatory agencies to align more directly with the executive's priorities. The broader pattern, visible across multiple departments, has been to install leadership that either openly questions the independent scientific establishment or declines to draw firm lines between political direction and agency judgment. Against that backdrop, a nominee's refusal to affirm the basic proposition that a sitting president can be mistaken is not a trivial bit of confirmation-hearing theater. It is a signal about how the nominee understands the relationship between the agency and the White House.
Makary himself is a surgeon and Johns Hopkins professor who built a substantial public profile as a medical commentator, often critical of what he described as an overly cautious medical establishment, particularly during the COVID-19 pandemic. He has supporters who argue that a more skeptical outsider is exactly what the FDA needs, that the agency has been too slow to approve promising treatments and too reluctant to challenge its own prior decisions. That argument has genuine force in some contexts. But the qualities that make for a productive institutional critic are not the same as the qualities that make for a trustworthy regulator. One requires willingness to challenge authority; the other requires the appearance, at minimum, of being insulated from it.
The likely consequences of the exchange depend heavily on what Makary does once confirmed, if he is confirmed. If his tenure proceeds in ways that look substantively independent — approvals and rejections made on evidentiary grounds, pushback on White House preferences when the science demands it — then the confirmation hearing moment will read as a politician's evasion, unpleasant but ultimately inconsequential. If, on the other hand, the FDA under his leadership makes decisions that track closely with administration priorities in ways that are hard to explain on scientific grounds alone, then this exchange will be cited as an early warning that was visible from the start.
The more immediate consequence is reputational and institutional. Scientists, physicians, public health researchers, and the international bodies that rely on FDA determinations for their own regulatory guidance will all have seen the exchange. The FDA's stamp of approval carries weight beyond American borders precisely because it has historically been seen as rigorous and politically buffered. Any erosion in that perception — even the early, speculative kind — affects how seriously the agency's judgments are taken abroad, and how willing domestic researchers are to trust the regulatory process they work within.
There is also a quieter consequence for the Senate itself, or at least for those members inclined to take seriously their role in confirming executive nominees. The purpose of a confirmation hearing is in part to elicit commitments about how a nominee will behave in office — whether they will follow the law, protect institutional norms, resist improper pressure. A nominee who will not state that the president can be wrong has, in effect, declined to make the most basic such commitment. That may not cost Makary the confirmation. But it narrows the space in which he can later claim independence as a defense if things go sideways.
What to watch next is straightforward. The first serious test will be any FDA decision on a politically charged question — a vaccine approval, a drug with contested evidence, a food safety ruling with economic implications for industries close to the administration — where the evidentiary record points in a direction the White House might prefer it did not. How Makary handles that moment will matter far more than anything said under the television lights of a Senate hearing room. Until then, Ars Technica's account of his non-answer stands as the clearest available window into the instincts of the man about to run one of the world's most consequential regulatory agencies.
